Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The hospital is being constructed at an estimated cost of around Rs. 6,000 crore and will provide healthcare facilities to the people of Faridabad and the entire NCR region
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The campaign aims to promote women’s health and wellness and urge them to visit the hospital for key medical check-ups
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Subscribe To Our Newsletter & Stay Updated
